Clinical Trials

Inclusion Criteria:

• Diagnosis/disease status: Patients with pathologically confirmed myeloma.

• For cross-sectional study, no additional required treatment schedule. For longitudinal study: Patients scheduled to undergo bone marrow biopsy (BMB) and/or induction therapy (or have gone through 1-2 cycles of induction therapy), followed by either bone marrow transplantation (BMT) or consolidation therapy.

• Age ≥ 18 years.

• Performance status: ECOG Status 0, 1 and 2.

• Women of child-bearing potential must agree to undergo a urine pregnancy screening per standard Radiology departmental protocol in place, to prevent imaging of pregnant patients.A female of child-bearing potential is any woman (regardless of sexual orientation, having undergone a tubal ligation, or remaining celibate by choice) who meets the following criteria:

  • Has not undergone a hysterectomy or bilateral oophorectomy; or

  • Has not been naturally postmenopausal for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months).

• Ability to understand and the willingness to sign a written informed consent.

 Exclusion Criteria: 

• Subjects may not be receiving any other investigational agents for the treatment of the cancer under study for longitudinal study. Patients enrolled for the cross-sectional study may receive other investigational agents.

• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that, in the opinion of the investigator, would limit compliance with study requirements.

• Female subjects must not be pregnant or nursing; since pregnancy is a contraindication to administration of gadolinium-based contrast agents.

• Any contraindication to MRI per Radiology Department’s routine protocol, e.g. MRI-incompatible objects, including but not limited to medical devices (e.g. pacemakers, AICD, etc.) and other foreign bodies.

• Known severe allergic reaction to Gadolinium-based contrast agents.

• Patients with uncontrollable claustrophobia, severe lower back pain, and uncontrollable tremors, to the point that it would render them unable to tolerate an MRI study.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 5/14/2025. Questions regarding updates should be directed to the study team contact.